Griffiths CEM

Hampton PJ

Lunt M

Mason KJ

Reynolds NJ

Smith CH

the BADBIR Study Group

Warren RB

Yiu ZZN

\ua9 2020 The Authors. British Journal of Dermatology published by John Wiley &amp; Sons Ltd on behalf of British Association of Dermatologists. Background: Real-world biologic drug survival is an important proxy measure for effectiveness. Predictors of drug survival may help patients with psoriasis choose between biologic therapies. Objectives: (i) To assess the relative drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis. (ii) To investigate predictors of biologic drug survival. Methods: A prospective cohort study was performed in the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) between November 2007 and August 2019. We performed survival analysis and fitted a flexible parametric survival model for biologic discontinuation due to ineffectiveness. Results: In total 9652 patients were included: 5543 starting on adalimumab (57\ub74%), 991 on secukinumab (10\ub73%) and 3118 on ustekinumab (32\ub73%). The overall drug survivals of adalimumab, secukinumab and ustekinumab in year 1 were 0\ub778 [95% confidence interval (CI) 0\ub777–0\ub779], 0\ub788 (95% CI 0\ub786–0\ub791) and 0\ub788 (95% CI 0\ub787–0\ub789), respectively. The adjusted hazard ratios (adjHRs) for discontinuation of adalimumab and secukinumab compared with ustekinumab were 2\ub711 (95% CI 1\ub776–2\ub754) and 0\ub767 (95% CI 0\ub740–1\ub711), respectively. The presence of psoriatic arthritis predicted for survival in the adalimumab and secukinumab cohorts (adjHR 0\ub767, 95% CI 0\ub751–0\ub788 and 0\ub770, 95% CI 0\ub740–1\ub724, respectively), but for discontinuation in the ustekinumab cohort (adjHR 1\ub742, 95% CI 1\ub712–1\ub781). Previous exposure to biologic therapies predicted for discontinuation in the ustekinumab and secukinumab cohorts (adjHR 1\ub754, 95% CI 1\ub726–1\ub789 and 1\ub749, 95% CI 0\ub791–2\ub745, respectively) and for survival in the adalimumab cohort (adjHR 0\ub771, 95% CI 0\ub755–0\ub792). Conclusions: Secukinumab and ustekinumab have similar sustained drug survival, while adalimumab has a lower drug survival in patients with psoriasis. Psoriatic arthritis and previous biologic experience were predictors with differential effects between the biologic therapies. What is already known about this topic?. There is conflicting evidence over the real-world drug survival of secukinumab in patients with psoriasis. Data from registries to date suggest that secukinumab has a lower drug survival than that reported from clinical trials. What does this study add?. This study found that secukinumab and ustekinumab had similar sustained drug survival in the real world, while the drug survival of adalimumab was lower, suggesting that the real-world drug survival of secukinumab is higher than previously reported. We found that psoriatic arthritis and previous biologic experience had differential effects on drug discontinuation in the three biologic cohorts. These predictors may help patients and clinicians choose the most appropriate biologic therapy

Newcastle University E-Prints

Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)

Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)

Abstract

Similar works

Full text

Available Versions

Newcastle University E-Prints